Darwin Global Management Ltd. Invests $317.62 Million in United Therapeutics Corporation $UTHR

Darwin Global Management Ltd. purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 748,550 shares of the biotechnology company’s stock, valued at approximately $317,617,000. United Therapeutics makes up about 8.8% of Darwin Global Management Ltd.’s investment portfolio, making the stock its 2nd largest holding.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. WealthCollab LLC raised its stake in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its position in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Wilmington Savings Fund Society FSB grew its position in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares in the last quarter. Abich Financial Wealth Management LLC bought a new stake in shares of United Therapeutics in the 3rd quarter valued at approximately $44,000. Finally, Geneos Wealth Management Inc. increased its holdings in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on UTHR. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. HC Wainwright increased their target price on shares of United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. TD Cowen raised their price target on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $548.09.

United Therapeutics Trading Up 0.6%

Shares of NASDAQ UTHR opened at $536.12 on Monday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $548.12. The company has a market cap of $23.50 billion, a price-to-earnings ratio of 19.22, a price-to-earnings-growth ratio of 1.93 and a beta of 0.84. The stock’s 50 day simple moving average is $486.67 and its 200 day simple moving average is $462.28.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. The firm’s revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the business earned $6.19 EPS. As a group, equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $513.18, for a total value of $5,644,980.00. Following the sale, the executive vice president directly owned 36,781 shares in the company, valued at $18,875,273.58. This trade represents a 23.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $502.79, for a total transaction of $11,312,775.00. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 307,930 shares of company stock valued at $150,132,812. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.